IASIS PHARMA is pleased to announce the launch of Sitagliptin/IASIS 25 mg/mL in the pharmaceutical form of an oral solution.

This is a new, innovative, and unique formulation belonging to the class of DPP-4i. It is an R&D and manufacturing product by IASIS PHARMA HELLAS.

Each 1 mL of Sitagliptin/IASIS oral solution contains sitagliptin hydrochloride monohydrate, equivalent to 25 mg of sitagliptin.

Superior to Solid Dosage Forms & Optimal Adhearence:

Sitagliptin/IASIS 25 mg/mL oral solution represents an excellent therapeutic option, specifically designed for patients facing swallowing difficulties (dysphagia). It provides patients with type 2 diabetes mellitus with rapid bioavailability, high dosing accuracy, ease of titration, and optimal treatment compliance.

Dosage and Administration :

The recommended dose is 100 mg (corresponding to 4 mL of oral solution) of sitagliptin once daily, taken with or without food. The solution is slightly opalescent, off-white, featuring a pleasant wild berry aroma.

Suitable for Special Patient Populations (Renal Impairment):

According to the Summary of Product Characteristics (SPC), no dose adjustment is required for patients with mild or moderate renal impairment (GFR ≥ 45 mL/min). For patients with GFR ≥ 30 to < 45 mL/min, the dose is adjusted to 50 mg (2 mL of solution) once daily, while for severe renal impairment (GFR < 30 mL/min), the dose is 25 mg (1 mL of solution) once daily.

Packaging & Ease of Use:

Sitagliptin/IASIS is supplied in an amber glass bottle. To ensure maximum dosing accuracy and convenience during administration, the pack includes a 5 mL graduated plastic syringe in 0.5 mL increments.

Divani Caravel Hotel/ Athens.

IASIS PHARMA participated in the 11^th Panhellenic Conference of Working Groups organized by the Hellenic Atherosclerosis Society. The conference was held from 05 to 06/12/2025, at the Divani Caravel Hotel in Athens, with the participation of many Healthcare Professionals.

Participants had the opportunity to learn more about the high-quality pharmaceutical products available from the company.

At IASIS PHARMA exhibition stand, the following products were displayed:

• RosuZet^®: Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths:5/10mg, 10/10mg, 20/10mg and 40/10mg.
• Rami–Amlo^®: a fixed-dose combination of Ramipril & Amlodipine in a single dosage form, in packages of 28 capsules, available in 4 strengths:
  5mg/5mg,
  5mg/10mg,
  10mg/5mg,
  10mg/10mg.
• Rami–Amlo plus^®, also an original fixed-dose combination of Ramipril – Amlodipine –Hydrochlorothiazide, which is available in packages of 30 capsules, in a wide range of strengths: 5mg/5mg/12,5 mg, 5 mg/5 mg/25 mg, 10 mg/5 mg/25 mg, 10 mg/10 mg/25 mg.

Italy   8 – 10/10/2024

IASIS PHARMA participated with great success at the Global Exhibition of the Pharmaceutical industry, CPhI.

The 34th edition of CPHI Worldwide took place at the Fiera Milano from 8-10 October 2024.

The organizers registered thousands of visitors and over 2,000 exhibitors, while hundreds were the professionals of the pharmaceutical industry who visited the IASIS PHARMA exhibition stand, receiving interesting information about the company’s unique and wide product portfolio.

More specifically, the company exhibited:

• IASIS PHARMA’sleading position in the Nitrofurantoin market, presenting the product in four (4) pharmaceutical formulations: IR tablets, IR capsules, PR capsules, oral suspension, with 36 MAs (Marketing Authorizations) in 23 countries.
• Its specialization in Contract Manufacturing Services in its 4 new, state-of-the-art production facilities.
• The wide range of prescription drugs in the form of effervescent tablets.
• An extremely interesting range of new products in Oral Suspension formin niche markets – New Product Pipeline.
• The facility that covers a large range of creams, gels and ointments, applying certified methods to ensure GMP & GLP standards.

IASIS PHARMA presented audio-visual material about the company’s new, state-of-the-art production facilities in Koropi, Attica.

During the three-day event, the IASIS PHARMA Management team succeeded in further strengthening its international partnerships as well as laying the foundations for new ones, further strengthening the company’s international presence.

Finally, after its successful participation in CPhI Fiera Milano 2024, IASIS PHARMA has already started prepared for the next CPhI on 28 – 30/10/2025 at Messe Frankfurt in Germany.

EXPECT MORE…

RosuZet® is the fixed dose combination of Rosuvastatin – Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents.

RosuZet® is indicated as an adjunct therapy to the diet for the treatment of primary hypercholesterolemia for adult patients adequately controlled with the drugs administered individually at the same dose level.

RosuZet®, as a fixed dose combination is indicated to reduce the risk of cardiovascular events as therapy for patients with coronary heart disease (CHD) and history of acute coronary syndrome (ACS), who are adequately controlled with individual agents administerted individually at the same dose.

It is available in packs of 30 film-coated tablets and in a wide dosage range:

• RosuZet® F.C.TAB (5+10)mg
• RosuZet® F.C.TAB (10+10)mg
• RosuZet® F.C.TAB (20+10)mg
• RosuZet® F.C.TAB (40+10)mg

Makedonia Palace

IASIS PHARMA participated in the 19^th International Congress of Dermatology & Venereology held on April 18-21, 2024, at the “Makedonia Palace” hotel in Thessaloniki.

The conference was organized by the Hellenic Dermatology & Venereology Society.

Greek Dermatologists attended the congress and had the chance to visit IASIS PHARMA exhibition stand and got informed of 3 important IASIS Dermatological products:

• Isotroin^®/ Isotretinoin (at the new & unique 30mg dosage) indicated for Severe forms of Acne that are resistant to treatment with systemically administered antibiotics and topical therapy. Isotroin^® 30mg  is added to the range of the other Isotroin^® strengths  (10mg, 20mg & 40mg).
• Combi^®, a combination of fluprednidene (1mg) + miconazole (20mg) cream for the treatment of Inflammatory Dermatomycoses.
• Modiwart^®/Ιmiquimod (12,5mg/sach), an innovative modifier of the immune response system indicated for the treatment of: External Genital Warts, Superficial Basal Cell Carcinomas and Aktinic Keratoses.

More specifically the excipient pigment of the effervescent tablets Calciform^® – Calcium Carbonate 500mg and Calciform D3^® – Calcium Carbonate & Cholecalciferol (1000mg +880 IU), has been removed resulting in color changing from orange to white.

Calciform^® family remains an excellent choice as an adjuvant treatment for Osteoporosis, Calcium & Vitamin D3 deficiency.

PRODUCT ADVANTAGES

• The easiest intake pharmaceutical form
• High absorption
• Complete dissolution without any residues
• Excellent orange flavor

For more information:

Tel: +30 210 2311031
Fax: +30 210 2315889
e-mail: iasis@iasispharma.gr

Dulac, Ioannina

IASIS PHARMA participated in the 1^st International Congress of Dermatology & Venereology held on November 01-05, 2023, at the “Du Lac” hotel in Ioannina. The conference was organized by the Hellenic Dermatology & Venereology Society together with the Dermatology & Venereology Society of Cyprus.

At IASIS PHARMA exhibition stand, the unique Isotroin 30mg was presented. Isotroin 30mg completes the range of the other Isotroin contents (10mg, 20mg & 40mg).

• Isotroin^®/Isotretinoin is indicated for the severe forms of Acne that are resistant to treatment with systemic antibiotics and topical therapy.

The following products were also presented:

• Modiwart^®/Ιmiquimod, an innovative modifier of the immune response system indicated for the treatment of: Condylomata acuminata, small Superficial Basal Cell Carcinomas and Aktinic keratoses.
• Combi^®, a combination of fluprednidene+miconazole cream for the treatment of Inflammatory Dermatomycoses such as Vulvovaginal Candidiasis.

Spain, 24-26/10/2023

IASIS PHARMA participated with great success in the Global Exhibition of the Pharmaceutical industry, CPhI.

For 2023, the exhibition was held on October 24 & 26, 2023 at Barcelona’s Gran Via Exhibition Center.

The organizers registered thousands of visitors and over 2,000 exhibitors, while hundreds were the professionals of the pharmaceutical industry who visited the IASIS PHARMA exhibition stand, receiving interesting information about the company’s unique and wide product portfolio.

More specifically, the company projected:

• IASIS PHARMA’s leading position in the Nitrofurantoin market, presenting the product in 4 forms: tabs (IR), capsules (IR, PR), oral suspension, with complete licensing procedures in 25 countries and 36 MAs (Marketing Authorizations).
• Its specialization in Contract Manufacturing Services in its 4 new, state-of-the-art production facilities.
• The wide range of prescription drugs in the form of effervescent tablets.
• An extremely interesting range of new products in Oral Suspension form in niche markets – New Product Pipeline.

IASIS PHARMA had the pleasure of hosting colleagues from its newly established company, IASIS PHARMA ROMANIA which is the latest milestone in the Group’s ongoing history.

IASIS PHARMA presented audio-visual material about the company’s new, state-of-the-art production facilities in Koropi, Attica, as well as the Mastic Research and Development Center of Chios, the construction of which has been completed and its operational work has already begun.

Also, during the three-day event, the IASIS PHARMA Management team succeeded in further strengthening its international partnerships, as well as laying the foundations for new ones, further strengthening the company’s international presence.

Finally, after its successful participation in CPhI Fira Barcelona Gran Via 2023, IASIS PHARMA renews the appointment with the global pharmaceutical industry for 8 – 10/10/2024 at CPhI Fiera Milano, Italy.

Thessaloniki Concert Hall

IASIS PHARMA participated in the “44th PANHELLENIC CONGRESS OF CARDIOLOGY” which held on October 12-14, 2023, at Thessaloniki Concert Hall.

The conference was organized by the Hellenic Society of Cardiology (HSC).

The Panhellenic Congress of Cardiology has established among Cardiologists and the Pharmaceutical Industry, as the Scientific Conference par excellence, with the largest participation of renowned Greek Scientists (Speakers, Presidents), high level of submitted abstracts and published poster presentations.

IASIS PHARMA presented at its exhibition stand the products:

•  Rami–Amlo®/ Ramipril & Amlodipine, the original fixed dose combination of angiotensin-converting enzyme inhibitors with calcium channel blockers. Therapeutic indication, substitution therapy in patients whose blood pressure is adequately controlled with ramipril and amlodipine simultaneously at the same dose level. (Box of 28 caps, Ramipril / Amlodipine: 5mg / 5mg, 5mg / 10mg, 10mg / 5mg, 10mg / 10mg).
•  Rami–Amlo plus®/ the original fixed dose combination of Ramipril – Amlodipine – Hydrochlorothiazide, indicated for the treatment of Hypertension. (Box of 30 caps, Ramipril / Amlodipine / Hydrochlorothiazide: 5 mg / 5 mg / 12,5 mg, 5 mg / 5 mg / 25 mg, 10 mg / 5 mg / 25 mg, 10 mg / 10 mg / 25 mg).
•  Licepler®/ Eplerenone: Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. (Box of 30 tabs at 25mg & 50mg).
•  Mag/IASIS®/ 243 mg Magnesium, main indications: Conditions of magnesium deficiency if these cannot be treated through nutrition. Disorders of muscle function, caused by confirmed magnesium deficiency (neuromuscular disorders, muscle cramps, such as gastrocnemius cramps, nocturnal cramps). (Box of 40 eff. tabs).

Divani Caravel Hotel Athens Greece

The Pharmaceutical Industry in Greece has completed 90 years since its foundation in 1933 as the Union of Pharmaceutical Laboratories which evolved into the Panhellenic Association of the Pharmaceutical Industry (P.E.F.).

On Tuesday, 26.09.23, at a brilliant anniversary event at the “Divani Caravel” hotel, Panhellenic Association of Pharmaceutical Industries honored the people who laid the foundations of the sector for the current edifice of the Greek pharmaceutical industry, its pioneers and founders whose values and vision are today a source of inspiration for the younger generations.

Within the framework of the event, the founders of the domestic pharmaceutical industry were awarded, including IASIS PHARMA (evolution-renaming of Farmanic-Chemipharma).

Farmanic Ltd. evolved into the thriving pharmaceutical company Farmanic S.A. by Konstantinos Generakis in 1985.

Chemipharma Pachis Ltd. was founded as a pharmaceutical company in 1996 by chemist Dr. Konstantinos S. Pachis and in a short period of time managed to establish himself in the difficult and extremely competitive field of medicine, establishing high standards of quality and ethics and presenting remarkable performances.

In 2004, Chemipharma Pachis acquired Farmanic, creating a new company, Farmanic-Chemipharma S.A. which in 2009 was renamed, IASIS PHARMA.

Mr. Konstantinos S. Pahis, Founder, CEO and President of IASIS PHARMA, in the context of the anniversary event of P.E.F. entitled “90 years of Greek Medicine”, received an Honorary Plaque as one of the Founders of the modern domestic pharmaceutical industry and referred to his vision, having already created a “healthy business cell”, which methodically develops and responds to new challenges, capitalizing on new trends and opportunities, while at the same time harmoniously combining people’s creativity with know-how and experience.

In his speech, Mr. Konstantinos S. Pahis made a special mention of the leaders of the domestic pharmaceutical industry who “laid solid foundations and planted deep roots from which blossomed exquisitely: the modern Greek Pharmaceutical Industry”, but he also referred to the current data of IASIS PHARMA with the two factories, the two subsidiaries, the modern Research & Development Center, export presence in 32 foreign countries and recently, the Chios Mastic Research Center, a joint venture with the Chios Mastic Producers Association in Chios.